Patents by Inventor Normand Blais

Normand Blais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC VIRAL VACCINE
    Publication number: 20220273789
    Abstract: The present invention relates to viral Fc receptor or immunogenic fragments thereof for treating a viral infection in a subject and, in particular, a herpes vims infection. The present invention also relates to a heterodimer comprising or consisting of an Fc receptor from a HSV vims or an immunogenic fragment thereof and a binding partner from said HSV vims or a fragment thereof, for use in therapy.
    Type: Application
    Filed: July 20, 2020
    Publication date: September 1, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand BLAIS, Cindy CASTADO, Johann MOLS, Lionel SACCONNAY, Marie TOUSSAINT, Newton Muchugu WAHOME, Giulietta MARUGGI
  • Fusion proteins and combination vaccines comprising Protein E and Pilin A
    Patent number: 11198707
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: December 14, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • UspA2 protein constructs and uses thereof
    Patent number: 10947280
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 16, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A
    Publication number: 20200331972
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 22, 2020
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • USPA2 PROTEIN CONSTRUCTS AND USES THEREOF
    Publication number: 20200325184
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand BLAIS, Cindy CASTADO, Patrick CHOMEZ, Marianne DEWERCHIN
  • UspA2 protein constructs and uses thereof
    Patent number: 10745449
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 18, 2020
    Assignee: GlaxoSmithKline
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • Fusion proteins and combination vaccines comprising haemophilus influenzae Protein E and Pilin A
    Patent number: 10730917
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 4, 2020
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • EXPRESSION SYSTEM
    Publication number: 20190322708
    Abstract: Methods for the production of a bacterial toxin such as diphtheria toxin, and methods for producing conjugates of a bacterial toxins, are provided.
    Type: Application
    Filed: July 11, 2019
    Publication date: October 24, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
  • Fusion proteins and combination vaccines comprising protein E and pilin A
    Patent number: 10214569
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: February 26, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • USPA2 PROTEIN CONSTRUCTS AND USES THEREOF
    Publication number: 20180354996
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: June 29, 2018
    Publication date: December 13, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • EXPRESSION SYSTEM
    Publication number: 20180258146
    Abstract: Methods for producing a conjugate of a bacterial toxin, including diphtheria toxin or CRM197, are provided.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand BLAIS, Philippe Marc Helene DEHOTTAY, Marianne DEWERCHIN, Philippe GOFFIN, Denis MARTIN
  • FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A
    Publication number: 20180222946
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: January 4, 2018
    Publication date: August 9, 2018
    Inventors: Normand BLAIS, Steve LABBE, Jan POOLMAN
  • UspA2 protein constructs and uses thereof
    Patent number: 10040832
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 7, 2018
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
  • Fusion proteins and combination vaccines comprising Protein E and Pilin A
    Patent number: 10023616
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 17, 2018
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • Expression system
    Patent number: 9994622
    Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 12, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
  • EXPRESSION SYSTEM
    Publication number: 20170137475
    Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.
    Type: Application
    Filed: July 14, 2016
    Publication date: May 18, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand BLAIS, Philippe Marc Helene DEHOTTAY, Marianne DEWERCHIN, Philippe GOFFIN, Denis MARTIN
  • FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A
    Publication number: 20170029472
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: June 30, 2016
    Publication date: February 2, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand BLAIS, Steve LABBE, Jan POOLMAN
  • USPA2 PROTEIN CONSTRUCTS AND USES THEREOF
    Publication number: 20170008932
    Abstract: The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: February 20, 2015
    Publication date: January 12, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand BLAIS, Cindy CASTADO, Patrick CHOMEZ, Marianne DEWERCHIN
  • Recombinant RSV vaccines
    Patent number: 9492531
    Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 15, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Guy Jean Marie Fernand Pierre Baudoux, Normand Blais, Sonya L. Cyr, Patrick Rheault, Jean-Louis Ruelle
  • FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A
    Publication number: 20160250313
    Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
    Type: Application
    Filed: February 18, 2016
    Publication date: September 1, 2016
    Inventors: Normand BLAIS, Steve LABBE, Jan POOLMAN